Conformis, Inc. (NASDAQ:CFMS) announced today that an independent,
retrospective review of hospital data has concluded that Conformis
iTotal® knee replacement technology is more cost-effective than
leading traditional, off-the-shelf implants. Importantly, this
study was independently performed with no sponsorship or funding
from Conformis.
The new abstract was presented by authors at the Orthopaedic
Research Society 2021 Annual Meeting (ORS 2021 Annual Meeting),
held in February 2021:
Custom-designed total knee arthroplasty is cost-effective in
comparison to a standard implant, Navin Fernando MD, Ann Chancellor
CCRC, Paul Manner MD, University of Washington, Seattle, WA, 2021
Proceedings of Orthopaedic Research Society, Paper 0980
The retrospective review was performed at a single medical
institution between 2016 and 2019 using a financial database and
electronic health records.
Patient demographics, total direct costs, length of stay (LOS)
and opioid use were all investigated. Two groups were evaluated for
procedures performed by a single surgeon, Dr. Paul Manner, MD,
Joint Replacement/Hip and Knee Arthritis Professor in the
Department of Orthopaedics and Sports Medicine at the University of
Washington in Seattle. Procedures for a control group were
performed by a second surgeon, Dr. Navin Fernando:
- Primary group – patient-specific implant (Conformis
iTotal®)
- Comparison group – traditional implant (Zimmer Persona®)
- Control group – traditional implant (Stryker Triathlon®)
performed by second surgeon
"We've been very pleased with the early outcomes for patients
with the Conformis knee. Patients report that the knee feels
more like a normal, healthy joint; they recover more quickly, and
are back to regular activity substantially faster than with
traditional, off-the-shelf implants,” said Dr. Paul Manner. “We
found that the episode of care cost is substantially less with the
Conformis knee because patients spent less time in the hospital,
and because the surgery can be performed in less time. Everyone
wins.”
“It is very gratifying to see Conformis technology once again
demonstrate its superior performance, as presented at the ORS 2021
Annual Meeting,” said Mark Augusti, President and Chief Executive
Officer, Conformis, Inc. “By designing and manufacturing
Conformis iTotal® knee replacement implants to fit each
individual’s unique anatomy, patients, surgeons, and medical
facilities benefit from expedited surgeries and shorter hospital
lengths of stay. Conformis iTotal® implants help to relieve chronic
joint pain, while also driving savings for hospitals and insurance
providers.”
The median patient age was 66 years old, and the median BMI was
31 for the three groups.
Mean LOS analysis:
- 1.35 days for Conformis iTotal® patients
- 1.99 days for Zimmer Persona® patients
- 1.83 for Stryker Triathlon® patients
Total direct costs analysis:
- $9,341 for Conformis iTotal® patients (savings of $1,006 to
$1,263 per patient)
- $10,347 for Zimmer Persona® patients
- $10,604 for Stryker Triathlon® patients
There was no apparent difference in morphine equivalent dose use
amongst the three groups.
The study concludes that total direct costs for hospital
admissions appear to be more cost-effective with the Conformis
iTotal® System, and variables such as operative time and LOS also
appear to favor a patient-specific implant over traditional,
off-the-shelf implants.
Three other comparative studies published between 2017 and 2019
also demonstrate that Conformis iTotal® implants drive savings for
hospitals and insurance companies:
- O’Connor, Mary, and Blau, Brittany, “Assessing the Economic
Value of Custom Implants." American Health & Drug Benefits.
2019, Vol.12, No. 2.
- Richard G. Buch, M.D., Robert W. Eberle, Jason Davis, M.D., and
Rylie Buch, MS, “Does Implant Design Affect Hospital Metrics and
Patents Outcomes? TKA Utilizing a ‘Fast-Track’ Protocol.”
Reconstructive Review. 2019, Vol. 9 No. 1.
- Culler et al., “Comparison of Adverse Event Rates and Hospital
Costs Between Customized Individually Made Implants and Standard
Off-the-Shelf Implants for Total Knee Arthroplasty.” Arthroplasty
Today 2017.
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit® Image-to-Implant® technology platform to develop,
manufacture, and sell joint replacement implants and instruments
that are individually sized and shaped, which we refer to as
personalized, individualized, or sometimes as customized, to fit
each patient’s unique anatomy. Conformis offers a broad line of
sterile, personalized knee and hip implants and single-use
instruments delivered to hospitals and ambulatory surgical centers.
In clinical studies, the Conformis iTotal® CR knee
replacement system demonstrated superior clinical outcomes,
including better function and greater patient satisfaction,
compared to traditional, off-the-shelf implants. Conformis owns or
exclusively in-licenses issued patents and pending patent
applications that cover personalized implants and patient-specific
instrumentation for all major joints.
For more information, visit www.conformis.com. To receive
future releases in e-mail alerts, sign up
at ir.conformis.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, including statements about the anticipated
timing of our product launches, and our financial position and
results, total revenue, product revenue, gross margin, operations
and growth, as well as other statements containing the words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” or “would” and similar
expressions, constitute forward-looking statements within the
meaning of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995. We may not actually achieve the
forecasts disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual financial results could differ materially from the
projections disclosed in the forward-looking statements we make as
a result of a variety of risks and uncertainties, including risks
related to our estimates and expectations regarding our revenue,
gross margin, expenses, revenue growth and other results of
operations, and the other risks and uncertainties described in the
“Risk Factors” sections of our public filings with
the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
our views as of the date hereof. We anticipate that subsequent
events and developments may cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we specifically disclaim any obligation
to do so. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the
date hereof.
CONTACT:
Investor Contact
ir@conformis.com
+1 (781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024